The dose conversion between formulations is not straightforward because bioavailability differs between delivery methods
2022;71: Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide Altimmune
The earliest expected approval is late 2027, following completion of the Phase 3 TRIUMPH program
Botanically-derived GLP-1 modulators including Lemme GLP-1 Daily Capsules, Arrae MB-1, and Veracity Metabolism Ignite are also gaining traction
RELATED: After GLP-1 Weight Loss, People Are Asking What Comes Next for Skin and Energy Achieving a healthy body composition requires monitoring these metrics closely to ensure the patient does not lose muscle inadvertently
Moreover, the comparison between DPP-4 inhibitors and placebo demonstrated no difference in their risk for MACE (RR = 0.99, 95% CI 0.931.06)